A missed renewal is two violations, not one
FDA's registration and listing window runs October 1 through December 31 every year, open right now. Miss it, and the failure to register is its own prohibited act under FD&C Act 301(p) — while every device the establishment ships in the meantime is separately misbranded under 502(o), a status the late filing doesn't undo.
By Connor Griggs — Regulatory & Quality Strategist
Right now, this week, every device establishment required to register with FDA owes it an annual filing. 21 CFR 807.22 sets the window the same way every year: October 1 through December 31, no exceptions for a quiet quarter or a reorganization in progress. An establishment that registered on time last year doesn’t carry that status forward — the rule treats registration as good for one fiscal year, renewed from scratch, every cycle. Miss the window, and what follows is not one violation. It is two, and they don’t resolve on the same day.
What the window actually asks for
Section 807.22 requires every establishment doing a covered operation — manufacturing, repackaging, relabeling, specification development — to confirm or update its registration and device listing in that three-month window, even when nothing about the device or the firm has changed. The confirmation itself is the obligation; a firm that simply does nothing because its listing was accurate last year has still missed the filing. FDA doesn’t treat the window as a courtesy reminder. It treats it as the only mechanism by which an establishment stays duly registered under section 510 of the Act for the fiscal year ahead.
Two statutes, not one
The failure to register is a violation by itself. FD&C Act section 301(p) (21 U.S.C. § 331(p)) makes the failure to register in accordance with section 510, on its own, a prohibited act — no shipped device required to trigger it. Separately, FD&C Act section 502(o) (21 U.S.C. § 352(o)) reaches the product: a device manufactured in an establishment not duly registered under section 510 is misbranded, full stop, regardless of anything else true about its quality or labeling. A December 2025 warning letter to a device firm cited exactly this combination — devices misbranded under 502(o) because the manufacturing establishment had not registered or listed for the fiscal year — showing the pairing is not a theoretical reading of the statute. It is how FDA actually writes the letter.
One missed filing creates a standing violation in the establishment and a separate, attaching violation in every unit that ships while it stands.
Why catching up doesn’t undo it
Filing the registration late stops the 301(p) exposure going forward — the establishment is registered again, as of whatever date the filing clears. It does not reach backward. Section 502(o) is written to the state of the establishment at the time a given device was manufactured, and a device shipped during the lapse was manufactured in an establishment that, on that date, was not duly registered. Nothing about filing the paperwork a month later changes what was true on the date of manufacture. The misbranding status attaches to that unit and travels with it; the late filing only closes the window for the units made afterward.
The practice
Treat the October–December renewal as a hard deadline tracked on its own calendar, not folded into whatever else a small RA team is already carrying that quarter — because the cost of missing it isn’t a late fee that a January filing cures. It is a status that attached to every device shipped in the gap and stays attached. This is regulatory intelligence about how the registration and misbranding provisions interact, never regulatory advice about a specific establishment’s filing history or exposure — that determination belongs with whoever is accountable for that firm’s registration.
Primary sources
- eCFR — 21 CFR 807.22, Times for establishment registration and device listing
- 21 U.S.C. § 331(p) — Prohibited acts (FD&C Act § 301(p))
- 21 U.S.C. § 352(o) — Misbranded drugs and devices (FD&C Act § 502(o))
- FDA — Device Registration and Listing
- FDA — Warning Letter, TomboyX PBC (Dec. 16, 2025)
- FDA Radar — what we monitor and how often
Regulatory intelligence, not regulatory advice. This post describes method and published FDA records as of its date; decisions about a specific device belong with your regulatory professional.